TY - JOUR
T1 - Photocarcinogenesis in mice by 4,4',6 trimethylangelicin plus UVA radiation
AU - Alcalay, J.
AU - Dall'Acqua, F.
AU - Kripke, M. L.
PY - 1990
Y1 - 1990
N2 - The carcinogenic effect of a new monofunctional psoralen 4,4',6-trimethylangelicin (TMA) plus UVA radiation was examined in C3H/HeN mice and compared with that of the parent compound angelicin. TMA carcinogenic effects were also with the previously reported effects of 8-methoxypsoralen. Using 2 different doses of TMA (25 μ and 250 μg) combined with 1 J/cm2 of UVA radiation, we found that 42% and 52% of the mice (respectively) developed tumors on the treated site. A dose of angelicin (215 μg) equimolar to the highest dose of TMA combined with 1 J/cm2 of UVA radiation produced tumors in 28% of the mice (P > 0.05). All tumors were squamous cell carcinomas. No metastases were found in any of the mice. We conclude that, although TMA + UVA radiation is carcinogenic in mice, it seems to be an equally active, but less phototoxic and less carcinogenic psoralen than 8-methoxypsoralen. The parent compound angelicin is not significantly less carcinogenic, and its clinical efficacy is poor.
AB - The carcinogenic effect of a new monofunctional psoralen 4,4',6-trimethylangelicin (TMA) plus UVA radiation was examined in C3H/HeN mice and compared with that of the parent compound angelicin. TMA carcinogenic effects were also with the previously reported effects of 8-methoxypsoralen. Using 2 different doses of TMA (25 μ and 250 μg) combined with 1 J/cm2 of UVA radiation, we found that 42% and 52% of the mice (respectively) developed tumors on the treated site. A dose of angelicin (215 μg) equimolar to the highest dose of TMA combined with 1 J/cm2 of UVA radiation produced tumors in 28% of the mice (P > 0.05). All tumors were squamous cell carcinomas. No metastases were found in any of the mice. We conclude that, although TMA + UVA radiation is carcinogenic in mice, it seems to be an equally active, but less phototoxic and less carcinogenic psoralen than 8-methoxypsoralen. The parent compound angelicin is not significantly less carcinogenic, and its clinical efficacy is poor.
UR - http://www.scopus.com/inward/record.url?scp=0025043710&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 2081117
AN - SCOPUS:0025043710
SN - 0108-9684
VL - 7
SP - 116
EP - 118
JO - Photodermatology Photoimmunology and Photomedicine
JF - Photodermatology Photoimmunology and Photomedicine
IS - 3
ER -